title: The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
abstract: Biological therapies are an important step in the management of Inflammatory Bowel Diseases. In consideration of high cost and safety issues there is the need to have clear recommendations for their use. Despite the American Gastroenterological Association and the European Crohn's and Colitis Organisation have published exhaustive Inflammatory Bowel Disease guidelines, national guidelines may be necessary as cultural values, economical and legal issues may differ between countries. For these reasons the Italian Society of Gastroenterology and the Italian Group for the study of Inflammatory Bowel Disease have decided to elaborate the Italian guidelines on the use of biologics in Inflammatory Bowel Disease. The following items have been chosen: definitions of active, inactive, steroid dependent and resistant disease; measures of activity; anti-tumor necrosis factor alpha therapy use in active steroid dependent and refractory luminal Crohn's Disease, in fistulising Crohn's Disease, in steroid dependent and resistant active Ulcerative Colitis; risk of cancer; risk of infections during anti-tumor necrosis factor alpha therapy; special situations. These guidelines are based on evidence from relevant medical literature and clinical experience of a national working group.
authors.affiliation: Department of Medicine, Pneumology and Nutrition Clinic, "V. Cervello" Hospital, Ospedali Riuniti "Villa Sofia-Cervello" University of Palermo, Italy. ambrogiorlando@tiscali.it
authors.forename: Ambrogio
authors.initials: A
authors.lastname: Orlando
authors.forename: Alessandro
authors.initials: A
authors.lastname: Armuzzi
authors.forename: Claudio
authors.initials: C
authors.lastname: Papi
authors.forename: Vito
authors.initials: V
authors.lastname: Annese
authors.forename: Sandro
authors.initials: S
authors.lastname: Ardizzone
authors.forename: Livia
authors.initials: L
authors.lastname: Biancone
authors.forename: Aurora
authors.initials: A
authors.lastname: Bortoli
authors.forename: Fabiana
authors.initials: F
authors.lastname: Castiglione
authors.forename: Renata
authors.initials: R
authors.lastname: D'Incà
authors.forename: Paolo
authors.initials: P
authors.lastname: Gionchetti
authors.forename: Anna
authors.initials: A
authors.lastname: Kohn
authors.forename: Gilberto
authors.initials: G
authors.lastname: Poggioli
authors.forename: Fernando
authors.initials: F
authors.lastname: Rizzello
authors.forename: Maurizio
authors.initials: M
authors.lastname: Vecchi
authors.forename: Mario
authors.initials: M
authors.lastname: Cottone
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001327:Autoimmune Diseases / Q000209:etiology; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D007412:Intestinal Fistula / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery; D007558:Italy; D009369:Neoplasms / Q000209:etiology; D009894:Opportunistic Infections / Q000209:etiology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D012074:Remission Induction / Q000379:methods; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab